Imfinzi 50 mg/mL 500 mg/10 mL
Imfinzi 50 mg/mL 500 mg/10 mL works by helping your immune system fight cancer.
Imfinzi 50 mg/mL 500 mg/10 mL is used in adults with PD-L1 (a protein that prevents the body's immune system from working sufficiently against cancer cells) level of 1% or more, has spread within the lungs without spreading to other parts of the body, cannot be removed by surgery, and chemotherapy and To treat a type of lung cancer called “non-small cell lung cancer (NSCLC)” that has not progressed after radiotherapy treatment, and previously untreated extensive small cell lung cancer (NSCLC) that has spread to the lungs (or other parts of the body) in adults. It is used to treat a type of lung cancer called lung cancer. In case of NSCLC, the treatment duration is up to one year if you see benefit. If the cancer progresses, it should be discontinued. If your cancer cells have mutations (genetic errors) called EGFR, ALK and ROS-1, IMFINZITM will not be used in your treatment. If you have questions about how Imfinzi works or why this medication has been prescribed for you, ask your doctor. Imfinzi will be given in combination with chemotherapy for SCLC. It is also important that you read the instructions for use of the chemotherapy you are receiving.
If you have any further questions about these medications, please consult your doctor.
- Imfinzi is available in packages containing one vial.
- Imfinzi contains 500 mg (50 mg/mL) of durvalumab in 10 mL of concentrated infusion solution in each vial. Imfinzi is sterile, preservative-free, clear to opaque, It is a colorless to slightly yellow solution that does not contain visible particles.
- Imfinzi contains the active ingredient durvalumab, which is an immune protein (monoclonal antibody: a type of protein designed to recognize a specific target substance in the body).
Imfinzi 50 mg/mL 500 mg/10 mL You can contact us to find out the price:Contact for detailed information Prospectus